ImmunoTargets and Therapy

ImmunoTargets and Therapy is pleased to announce a new Article Collection dedicated to examining CombImmunoTherapy (CIT) as a game-changing oncology treatment strategy.

This Collection, edited by the Editor-In-Chief Prof. Michael R. Shurin, is part of the new Game Changer series of Article Collections, focusing on breakthrough therapies, drugs, and technologies that have significantly altered the standard of care, leading to game-changing improvements in patient outcomes.

In 2011, the first immunotherapy for cancer was approved. Since then, the FDA has approved at least 11 immune checkpoint inhibitors and other types of immunotherapies, including CAR T-cell therapies. Currently, there are more than 1,000 immunotherapy clinical trials underway across the United States alone, with 15-20% of patients experiencing robust results. While immunotherapy has significant promise, traditional methods of cancer treatment, such as chemotherapy and radiation therapy, still prevail as the first line of treatment. As we learn more about factors such as the tumor microenvironment that influence treatment efficacy, one thing remains clear – there is a great need for personalized combination therapy. CIT provides a more tailored approach, allowing oncologists flexibility to effectively treat each individual patient.

While this call is open to receive manuscripts highlighting all aspects of CIT, the Editors are particularly interested in manuscripts relating to the following areas:
• Preclinical models investigating combinatorial immunotherapy strategies
• Promising combinatorial approaches currently in trial
• Interaction, safety, and contraindication data
• Current therapeutic drugs/antibodies in the pipeline
• Mechanistic action, targets, and immune effects of CIT
• Immunotherapy in combination with traditional chemotherapy and/or radiation therapy
• Cancer vaccines for CIT
• Combinational immunotherapy of patients with cancer and comorbid immune-mediated diseases

Papers published within the Game Changer series will benefit from additional promotional activities across Taylor and Francis, increasing the discoverability and visibility of your research.

Submitting authors are eligible for a 20% discount on the Article Publishing charge by applying the following code at the point of submission: 0A8F9. All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your paper on our website. The deadline for submitting manuscripts is 1 June 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor, Ashley Ambros at [email protected].

View all papers in this article collection

ImmunoTargets and Therapy is pleased to announce a new Article Collection dedicated to examining immunotherapy strategies to treat comorbid immune-mediated diseases.

Patients with comorbid immune-mediated diseases have at least two or more autoimmune, allergic, infectious or inflammatory diseases that significantly impact their quality of life. Some conditions typically co-occur together, such as Sjogren’s Syndrome and Systemic Lupus Erythematosus. Other diseases may be a result of shared inflammatory signaling pathways or caused by the primary immune-mediated disease. Treating patients with comorbid immune-mediated diseases presents a unique challenge, as treatment may require a multidrug regimen with multiple opportunities for drug interaction.

In this Article Collection, we seek to explore the mechanistic underpinnings of immune-mediated disease comorbidities and potential opportunities for immunotherapeutic treatment. While this call is open to receive manuscripts highlighting all aspects of comorbid immune-mediated disease therapy, the Editors are particularly interested in manuscripts relating to the following areas:
• Cell-based therapeutics such as stem cell and CAR-T cell-mediated therapies
• Novel preclinical models, shared disease pathway targets, and mechanism of action studies
• Emerging immunotherapeutic treatment options and strategies
• Clinical management strategies such as combination therapy and therapeutic resistance
• Special patient populations, including immune disorders involving multiple systems
• Immune-related adverse events while treating comorbid diseases
• New use cases for already-approved immunotherapy to target multiple disease pathways
• Regulation of immunological balance in treating comorbid diseases

All manuscripts submitted to this Article Collection will undergo desk assessment and a full peer review. Please review the journal scope and author submission instructions prior to submitting a manuscript as it will be rejected if it does not fall within the scope of the journal.

Please submit your paper on our website, quoting the promo code 86788 to indicate that the paper is intended for the Article C0llection. The deadline for submitting manuscripts is 1 June 2026.

If you have any queries regarding the Article Collection or would like to discuss a submission, please email the Commissioning Editor, Ashley Ambros at [email protected].

View all papers in this article collection

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Future-Ready CAR-T Cells: Integrating Gene Editing, Multi-Antigen Targeting, Translational Advances and Microenvironment Reprogramming" Guest Edited by Dr. Vinay Kumar and Dr. Anuradha Tyagi in ImmunoTargets and Therapy.

Chimeric Antigen Receptor T-cell (CAR-T) therapies have transformed the landscape of cancer treatment, offering unprecedented outcomes in relapsed and refractory hematologic malignancies. Despite these breakthroughs, significant obstacles; including antigen escape, T-cell exhaustion, off-tumor toxicity, limited durability of responses, and restricted success in solid tumors still constrain their broader therapeutic potential. In parallel, rapid innovations in gene editing, synthetic biology, vector engineering, and tumor microenvironment modulation are driving the next generation of CAR-T technologies. Given the expanding field and urgent need for new solutions, this Article Collection aims to gather cutting-edge research and authoritative reviews that highlight transformative advances, emerging challenges, and forward-looking strategies in CAR-T cell–based immunotherapies.

Global research and clinical activity in CAR-T therapy is rapidly accelerating, yet critical gaps remain in mechanistic understanding, therapeutic optimization, and practical implementation. A focused collection in ImmunoTargets and Therapy will provide a comprehensive and influential resource for clinicians, immunologists, translational scientists, and biotech innovators, catalyzing advancements that can reshape patient outcomes. Hence this Article Collection, will serve as a forward-looking platform to capture breakthrough developments and foster innovation in one of the most rapidly evolving domains of modern immunotherapy.

This Collection welcomes high-impact original research, reviews, mini-reviews, perspectives/commentaries, methodology papers and graphical reviews/visual communications focusing on the diverse scientific and translational innovations reshaping CAR-T therapy. Key themes include, but are not limited to: 1. Engineering Next-Generation CAR-T Cells; 2. Addressing Antigen Escape and Heterogeneity; 3, Toxicity Mitigation and Safety Engineering; 4, Advanced Gene-Editing and Synthetic Engineering Platforms; 5, Innovations in Tumor Microenvironment (TME) Reprogramming; 6, Clinical Advances, Safety Innovations, and Combination Therapies; 7, Expanding CAR-T Horizons Beyond Cancer

Keywords

1. CAR-T cell therapy
2. Next-generation CAR-T
3. Multi-antigen targeting
4. Tumor microenvironment (TME) modulation
5. Clinical trial innovations

All manuscripts submitted to this Article Collection will undergo a full peer-review. Please review the journal scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code A6829 to indicate that your submission is for consideration in this Article Collection. The deadline for submitting manuscripts is 15 October 2026.

Please contact Ashley Ambros at [email protected] with any queries and discount codes regarding this Article Collection.

Guest Advisors

Vinay Kumar, Penn State University

[email protected]

Dr. Vinay Kumar is a Researcher (junior faculty) at the Heart and Vascular Institute, Pennsylvania State University, where his work focuses on dissecting dysregulated innate and adaptive immune networks in myocardial infarction (MI) and chronic heart failure (HF). His research emphasizes understanding the roles of distinct T-cell subsets and the time-dependent phenotypic shifts these cells undergo during chronic HF. Additionally, Dr. Kumar is dedicated to developing innovative immunomodulatory strategies to reverse pathological immune alterations and facilitate their translation from bench to bedside.

Anuradha Tyagi, Department of cBRN, Institute of Nuclear Medicine & Allied Sciences

[email protected]

Dr. Anuradha Tyagi is a biomedical researcher specializing in inflammation biology, wound healing, and host–pathogen interactions. Her work demonstrates that timely modulation of the inflammatory phase is crucial for proper wound closure and tissue repair, particularly in conditions like radiation dermatitis. She has highlighted the therapeutic potential of secondary bile acids in chronic wound management, showing their ability to inhibit biofilm formation, neutralize bacterial virulence factors, modulate pro-inflammatory cytokines, and promote angiogenesis. Dr. Tyagi’s research advances our understanding of immune responses, microbial dynamics, and tissue regeneration, with important translational implications for chronic wound therapy.

View all papers in this article collection